Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical StudyArticle Published on 2020-11-282022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] age Analysis antibodies antibody antibody isotype Antibody titers Asymptomatic asymptomatic patients clinical collected Complete convalescent plasma correlated COVID-19 domain Donor donors ELISA evaluated first symptom Hospitalization hospitalized patient in-house ELISA Increased median time Multiplex assay neutralize Novel coronavirus nucleocapsid patients Phase 2 positive PCR Protein pseudotype RBD Recombinant spike protein response SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 virus selected significantly symptom onset the antibody response virus-neutralizing antibody [DOI] 10.3390/microorganisms8121885 PMC 바로가기 [Article Type] Article
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trialCOVID-19(ZILU-COV)로 인한 급성 저산소 호흡 부전 환자의 질루코플란: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-11-192022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 24 hour 24 hours acute hypoxic respiratory failure acute lung injury acute respiratory distress syndrome addition Adult patient alveolar pressure antibiotic Antibiotics anticipated arterial pressure Bacterial blinded Blinding Caregivers ceftriaxone characterized ciprofloxacin clinical Clinical course Combination comparator comparator Patients complement complement C5 inhibition complement pathways complement system component components control arm control group COVID-19 COVID-19 patient CT scan Cytokine release syndrome defined discharge discharged patient discharged patients disease dissemination Effect Efficacy and safety element eligibility criteria EudraCT exclusion criteria experimental arm Fungal infection history hospital discharge hospitalized patient hospitalized patients hospitals hypoxia hypoxic respiratory failure ICU ICUs Identifier improving oxygenation inclusion criteria individual Infection inhibiting inhibitor Interactive Web Response System invasive IV infusion LDH lead lung Lung injury lymphopenia Mechanical mechanical ventilation median meningococcal disease meningococcal infections number objective Open-label open-label trial outcome oxygen oxygen) Oxygenation pandemic PaO parameters Partial participant Participants Patient Phase 2 predict predisposition primary endpoint promote prophylactic antibiotics protocol randomisation randomised randomised controlled trial randomization Randomized receive recent recruited recruitment REDCap Registered repair mechanism Respiratory failure response Sample size SARS-COV-2 infection Serum ferritin SIGN SpO2 Standard of care status Study protocol subcutaneously supplemental oxygen supplementary material System systemic cytokine release syndrome Trial Trial registration Ventilation Version Web website zilucoplan [DOI] 10.1186/s13063-020-04884-0 PMC 바로가기 [Article Type] Letter
TOCIVID-19 – A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocolTOCIVID-19 - COVID-19 폐렴 환자 치료에서 토실리주맙의 효능 및 내약성에 대한 다기관 연구. 연구 프로토콜Article Published on 2020-11-012022-09-11 Journal: Contemporary clinical trials [Category] MERS, 임상, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome administration ambient Analysis can not co-primary endpoints Cohort complication of COVID-19 COVID-19 COVID-19 pneumonia Critical cytokine Cytokine storm dose Efficacy eligible enrolled EudraCT hospitalized patient hospitalized patients Host immune response humanized monoclonal antibody IL-6 IL-6 receptor include intravenous Intravenous administration Intubated Italian population lethality rate lethality rates multicenter multicentre NCT04317092 oxygen oxygen saturation Patient patients patients with COVID-19 Phase 2 Phase 2 study Pneumonia primary analysis prospective cohort protocol reached receive receptor recombinant humanized monoclonal antibody Registered respiratory respiratory distress Respiratory distress syndrome respiratory impairment Respiratory Support Result Sample Sample size single-arm phase 2 single-arm phase 2 study syndrome the cytokine storm Tocilizumab TOCIVID-19 Tolerability treat Treatment Trial with COVID-19 [DOI] 10.1016/j.cct.2020.106165 PMC 바로가기 [Article Type] Article
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial코로나19 폐렴 환자를 위한 토실리주맙. 단일군 TOCIVID-19 전향적 시험Research Published on 2020-10-212022-08-13 Journal: Journal of Translational Medicine [Category] MERS, SARS, 임상, [키워드] Analysis baseline blocks pro-inflammatory activity cause of death co-primary endpoints Cohort coronavirus COVID-19 COVID-19 patients dataset death death in COVID-19 drug toxicity effective enrolled EudraCT evaluated expected exploratory greater IL-6 intention-to-treat Interaction interleukin interleukin-6 involved ITT lethality rate lethality rates mechanical respiratory Mortality multicenter multivariable logistic regression NCT04317092 negatively affected null hypothesis Older age PaO2/FiO2 ratio Pathogenesis Patient patients patients with COVID-19 Phase 2 Pneumonia pro-inflammatory activity prognostic variable prognostic variables prospective cohort Prospective trial reduced Registration reported respiratory Respiratory Support Result Safety single-arm statistically significant Steroids subject Support survival Tocilizumab TOCIVID-19 Toxicity Trial use of steroid was used [DOI] 10.1186/s12967-020-02573-9 PMC 바로가기 [Article Type] Research
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agentsReview Published on 2020-10-152022-10-28 Journal: Virology Journal [Category] COVID-19, MERS, SARS, [키워드] activated acute respiratory distress acute respiratory distress syndrome alveolar macrophage angiotensin converting enzyme 2 antibody Antiviral article B cell bind blunt caused characterized China Chloroquine Combination coronavirus 2 Coronavirus disease 2019 COVID-19 COVID-19 illness CRS cytokine Cytokine release syndrome Cytokine storm drug target dysregulation enzyme epithelial cells Fever global pandemic hemodynamic instability hypoxia identify IFN IL-1β immune system immunological mechanism Immunotherapy imperative Innate immunity involved manifestation Necrosis Novel coronavirus nuclear Obstetric organ damage overcome Pathogenesis pathophysiology Patient pediatric Phase 2 Phase 3 receptor reduce respiratory respiratory symptoms responsible resulting SARS-CoV-2 SARS-CoV-2 epidemiology severe COVID-19 Signaling syndrome therapeutic agent therapeutic interventions tissue injury TLR Tocilizumab triggering Viral load viral replication virus Virus-host interaction Virus-host interactions World Health Organization worsening [DOI] 10.1186/s12985-020-01415-w PMC 바로가기 [Article Type] Review
Measures to Protect the Health and Safety of Massachusetts Employees Who Must Work at the Workplace During the SARS-CoV-2 PandemicDocuments Published on 2020-09-222022-10-29 Journal: New Solutions [Category] COVID-19, SARS, [키워드] Coalition COVID-19 economic reopening employee Health Massachusett Massachusetts measure must Novel coronavirus occupational pandemic Phase 2 recommendation Safety SARS-CoV-2 Spread the SARS-CoV-2 was reduced work worker health and safety Workplace [DOI] 10.1177/1048291120960229 PMC 바로가기 [Article Type] Documents
What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?Review Published on 2020-08-282022-10-28 Journal: Vaccine: X [Category] COVID-19, [키워드] antibodies antibody antibody production Antibody Response Antibody-dependent enhancement Antigen Blood boost breadth CD4 CD8 CD8 T-cell CD8 T-cells Cell-mediated immunity clinical disease Clinical outcome Clinical severity convalescent Coronavirus infection Coronavirus infections correlated Coverage COVID-19 cross-reactive described develop disease Durable immunity epitope Human immune protection immune response immunized induce Laboratory less marker mild infections natural infection neutralizing antibody nightmare pathogenic pathology Phase 2 Progress Protective protective immunity public health resulting SARS SARS-CoV-2 SARS-CoV2 Spike protein Support T cell lifespan T cell response T-cell epitopes T-cell Response T-cells trials vaccination Vaccine vaccine candidate Vaccines yellow Yellow Fever Vaccine [DOI] 10.1016/j.jvacx.2020.100076 PMC 바로가기 [Article Type] Review
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic studyC형 간염 바이러스 감염 임산부에 대한 레디파스비르 + 소포스부비르: 1상 약동학 연구Article Published on 2020-08-132022-09-06 Journal: The Lancet. Microbe [Category] Communicable Disease, [키워드] All participants Alter analysed AUC changes in Child child health clinically concentration–time curve Course development dosing interval during pregnancy effective enrolled Epidemic finding funding genotype 1 geometric geometric mean geometric mean ratio gestation HCV Hepatitis hepatitis C hepatitis C virus Human Human Development Infants Infection Intensive Intervention ledipasvir Magee-Womens Hospital nine Open-label opioid parameter participant participated pharmacokinetic pharmacokinetics Phase 1 phase 1 study Phase 2 Physiological changes Pittsburgh Pregnancy pregnant pregnant women primary analysis Primary outcome reduce Registered Safe screened sofosbuvir sofosbuvir) Transmission treat Trial USA virus was used women [DOI] 10.1016/S2666-5247(20)30062-8 PMC 바로가기 [Article Type] Article
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialACCORD: 입원 환자의 COVID-19 치료를 위한 여러 후보 약제의 효능과 안전성을 평가하기 위한 다기관, 원활한, 2상 적응형 무작위화 플랫폼 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 a BTK inhibitor Acalabrutinib adaptive added adjusted agent Amendment analyses Analysis Anti-viral approval Arm baseline bemcentinib Blinding block BTK inhibitor candidate Candidates cause caused changed clinical Clinical characteristics Clinical improvement clinically comparator complement COVID COVID-19 current Day discharge disease dissemination dropped Efficacy element Endpoint England estimation EudraCT evaluate Evidence evidence of experimental arm GRADE group help heparin hospital hospitalised include Inflammatory response inhibitor Ireland IRT Mask Master protocol Mild Mild disease monoclonal antibody Multiple nasal prongs National non-invasive ventilation number objective open open label Ordinal Scale outcome oxygen Oxygen therapy oxygen therapy) participant Patient performed Phase 2 phase II platform proceed protocol protocols provide randomisation randomised randomised controlled randomised controlled trial randomization recruited recruitment reduce Registered Regulatory reported Respiratory failure response response rate Safety Sample size SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein seamless selected severity shown SOC Spike protein Stage stage 2 stages Standard of care status stratified Study protocol sustained Task Force technology the spike protein the WHO therapy time treat Treatment treatment of COVID-19 Trial Trial registration Viral viral infection virus website with COVID-19 working zilucoplan [DOI] 10.1186/s13063-020-04584-9 PMC 바로가기 [Article Type] Letter
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agentsResearch article Published on 2020-07-012022-10-05 Journal: Medical Hypotheses [Category] 치료제, [키워드] antibody antiviral agent Antiviral agents blocking Blood Cancer cancers CD8 CD8+ CD8+ cell Cell Chloroquine clinical trials COVID-19 COVID-19 infected patient COVID-19 patient CTLs cytokine secretion cytotoxic cytotoxicity disease Disease progression effective functional generate healthy controls healthy individuals Host immune response Immunity individual inhibiting inhibitory Innate innate immune response Innate immunity interferon lymphocyte mechanism mild infection modulated Monalizumab natural neutrophil NK cell NK cell function NK cells NKG2A Novel coronavirus outbreak over-expressing overexpression Patient Phase 2 Potential treatment receptor receptors reduced required resulting SARS SARS-CoV-2 severe COVID-19 Severe infection Side effect significantly significantly lower T-cell treated tumor growth tumor progression viral pathogen viruses weakened immune system [DOI] 10.1016/j.mehy.2020.109777 [Article Type] Research article